Becker, G.; Da Silva, S.; Sabo, A.-N.; Antal, M.C.; Kemmel, V.; Monassier, L.
Blood–Brain Barrier Permeability: Is 5-Hydroxytryptamine Receptor Type 4 a Game Changer? Pharmaceutics 2021, 13, 1856.
https://doi.org/10.3390/pharmaceutics13111856
AMA Style
Becker G, Da Silva S, Sabo A-N, Antal MC, Kemmel V, Monassier L.
Blood–Brain Barrier Permeability: Is 5-Hydroxytryptamine Receptor Type 4 a Game Changer? Pharmaceutics. 2021; 13(11):1856.
https://doi.org/10.3390/pharmaceutics13111856
Chicago/Turabian Style
Becker, Guillaume, Sylvia Da Silva, Amelia-Naomi Sabo, Maria Cristina Antal, VĂ©ronique Kemmel, and Laurent Monassier.
2021. "Blood–Brain Barrier Permeability: Is 5-Hydroxytryptamine Receptor Type 4 a Game Changer?" Pharmaceutics 13, no. 11: 1856.
https://doi.org/10.3390/pharmaceutics13111856
APA Style
Becker, G., Da Silva, S., Sabo, A. -N., Antal, M. C., Kemmel, V., & Monassier, L.
(2021). Blood–Brain Barrier Permeability: Is 5-Hydroxytryptamine Receptor Type 4 a Game Changer? Pharmaceutics, 13(11), 1856.
https://doi.org/10.3390/pharmaceutics13111856